PharmaShots | Incisive News in 3 Shots

Subscribe Now

MHLW

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial C...

September 27, 2021

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metast...

August 25, 2021

Chugai Files an Application with MHLW for an Additional Indication of Tecentriq as an Adjuvant Treatment for NSCLC in Japan

Chugai Files an Application with MHLW for an Additional Indication of Tecentriq as an Adjuvant Treatment for NSCLC in Japan

July 8, 2021

Bayer's Verquvo (vericiguat) Receives MHLW's Approval for Chronic Heart Failure

Bayer's Verquvo (vericiguat) Receives MHLW's Approval for Chronic Heart Failure

June 24, 2021

Chugai's Evrysdi (risdiplam) Receives MHLW's Approval for the Treatment of Spinal Muscular Atrophy

Chugai's Evrysdi (risdiplam) Receives MHLW's Approval for the Treatment of Spinal Muscular Atrophy

June 24, 2021

$Chugai's Polivy Receives MHLW's Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma$

Chugai's Polivy Receives MHLW's Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma

March 25, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us